

# SCC Coaching Call

Cole Stanley, MD, CCFP

Medical Lead, Provincial BOOST Collaborative

May 30, 2019





# Disclosures

## **Dr. Stanley**

- Travel grants received for conference attendance from the following
  - 2017 – Gilead Sciences
  - 2016 – Canadian Association for HIV Research (with support from Viiv), Gilead Sciences
- Advisory Board – Viiv Canada, March 2019
- Mitigating bias
  - No discussion of specific HIV or Hep C therapy in this talk

# List of topics we can cover

- 1) Forming your QI team
- 2) Getting a QI coach
- 3) Meeting regularly
- 4) Developing aims
- 5) Measuring
- 6) Testing changes
- 7) Barriers you are encountering
- 8) Tips for other teams



# START WITH WHY

SINEK





***Daniel***

***Alex***

***Paul***



- **Withdrawal suppression**
- **Decreased illicit opioid (and cocaine) use**
- **Reduced risk of HCV/HIV**
- **Better HIV control**

## **Opioid agonist therapy**

- **Decreased criminal justice system involvement**
- **Significantly reduced mortality (both all-cause and substance-related)**

**Retention** on methadone and buprenorphine is associated with ***substantial reductions in the rate of all cause and overdose mortality***






## ***B.C. Coroner's data...***

### ***Suboxone saved Sabrina?***




## **Top Relevant Drugs Detected Among Illicit Drug Overdose Deaths, 2016-2017**




April 5, 2018

## Majority started on OAT, minority retained on therapy for adequate period



# SUBSTANCE USE TREATMENT JOURNEY MAP


what do peers experience?



<https://bcpsqc.ca/documents/2017/12/Journey-Mapping-Substance-Use-Treatment-Report.pdf>








100 expired recently

80 actually expired


40 follow-up documented



## ***Discontinuation rate is highest during first few months of therapy***



- Standardize clinical data entry
- Regular client feedback surveys
- Reminder calls for appointments
- Reminder calls for expiring prescriptions
- Assertive outreach for clients lost to care
- Follow-up on missed oOAT dose faxes from pharmacies
- Work-flow changes to support Suboxone inductions





# Testing Changes – PDOSA Cycles

---

## PLAN

What will happen if we try something different?  
What question do we want to ask & what is our prediction?  
Who will carry this out? (When? How? Where?)

## DO

Let's try it!  
Carry out your plan  
Document any problems  
Begin data analysis

## STUDY

Did it work?  
Complete data analysis  
Compare results to your prediction  
Summarize your results


## ACT

What's next?  
Ready to implement/adapt?  
Try something else/abandon?  
Next cycle?

# Collaborative Aims

- **95% of clients have an active OAT prescription**
- **95% of those clients with an active OAT prescription will be retained on therapy for greater than 3 months**
- **100% of teams have a process to monitor and incorporate the patient voice**

# Provincial Teams



1. Dr. Peter Centre
2. DTES Connections - VCH
3. Foundry Vancouver Granville - PHC
4. Dr. Rodney Glynn-Morris - Vancouver
5. John Ruedy Clinic - PHC
6. Medicare Medical Clinic - Vancouver
7. Overdose Outreach Team - VCH
8. START Program - VCH
9. Urban Indigenous Healing and Health Centre
10. Vancouver Detox - VCH
11. Vancouver Native Health Society Clinic
12. Vancouver Rapid Access Addiction Clinic - PHC
13. North Shore OAT Services - VCH
14. Sea to Sky OAT Program - VCH
15. Sunshine Coast MHSU Services - VCH
16. Alouette Addiction Services - FH
17. Burnaby MHSU OAT Clinic - FH
18. Correctional Health Services - Surrey Pretrial CTT - PHSA
19. Correctional Health Services - Kamloops Regional Correctional Centre CTT - PHSA
20. Roshni Clinic - FH
21. Quibble Creek OAT Clinic - FH
22. Riverstone OAT Program - Chilliwack - FH
23. AVI Health Centre - Nanaimo
24. AVI Health Centre - Westshore
25. Dr. Erika Kellerhals - Campbell River
26. Health Connections Clinic - VIHA
27. Dr. Jane Clelland & Dr. Susan Booth - Oceanside
28. Phoenix Wellness - Duncan
29. Victoria Rapid Access Addiction Clinic - VIHA
30. Central Interior Native Health Clinic - NH
31. Cornerstone Chemical Dependency Clinic - Williams Lake
32. Kelowna MHSU Services - IH


# Team Aims

To align with Collaborative aims

S




M




A



R




T





# Model for Improvement





Original research

# Evolving quality improvement support strategies to improve Plan–Do–Study–Act cycle fidelity: a retrospective mixed-methods study

Chris McNicholas<sup>1, 2</sup>, Laura Lennox<sup>1</sup>, Thomas Woodcock<sup>1</sup>, Derek Bell<sup>1</sup>, Julie E Reed<sup>1</sup>



Principle	Measure
Documentation	All PDSA cycle stages documented  'Study' section documented in past tense
Learning activity	Learning activity present in PDSA cycle
Prediction	Explicit prediction documented in PDSA cycle

Iterative cycles	PDSA cycle within iterative series of 2 or more cycles
Small-scale testing	PDSA iterative series increasing testing scale
Use of data over time	PDSA iterative series using regular data over time

# Project Progress Assessment Scale

---


- 0.5** - Intent to Participate
- 1.0** - Charter and team established
- 1.5** - Planning for the project has begun
- 2.0** - Activity, but no changes
- 2.5** - Changes tested, but no improvement
- 3.0** - Modest improvement
- 3.5** - Improvement
- 4.0** - Significant improvement
- 4.5** - Sustainable improvement
- 5.0** - Outstanding sustainable results



# ***Who are we measuring?***







## Population of Focus


1 – our clients with OUD

2 - we are primary OAT provider


3 – have active OAT rx

4 – retained on OAT >3mos

#  
*clients*



# Population of Focus









<https://pollev.com/ranag760>





# 304.0 opioid use disorder



BRITISH COLUMBIA  
CENTRE ON  
**SUBSTANCE USE**

*Networking researchers, educators & care providers*

**DSM-5 CLINICAL DIAGNOSTIC CRITERIA  
FOR OPIOID USE DISORDER<sup>1</sup>**

---





**MRP – Dr. Cole Stanley**







**POS – John Ruedy Clinic**

















*Start small*





	A	B	C	D	E	F	G
1	Patient ID	OAT	dose	Start	End	MRSD	MRP
2	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X
3	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y
4	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y
5	4	none					Dr Z
6	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X





I2									
	A	B	C	D	E	F	G	H	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85




***Today is Jan 31, 2019***

	A	B	C	D	E	F	G	H	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

	A	B	C	D	E	F	G	H	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

***Partial POF = 5***



**X**

***Active Rx = 3***







1mos

2mos

3mos

***RTN > 3mos = 1***





	A	B	C	D	E	F	G	H	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

	A	B	C	D	E	F	G	H	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

	A	B	C	D	E	F	G	H	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

	A	B	C	D	E	F	G	H	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

	A	B	C	D	E	F	G	H	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

	A	B	C	D	E	F	G	H	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

